Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS | MicrobiomeTrials← Back to trialsNCT07322003
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-02-01Est. Completion: 2028-03
Enrollment target: 500 participants Locations- University of South Florida, Florida City, Florida, United States
- Emory University, Atlanta, Georgia, United States
- University of Kansas, Fairway, Kansas, United States
- Sean M. Healey & AMG Center for ALS, Boston, Massachusetts, United States
- Somnos Clinical Research, Lincoln, Nebraska, United States
- Neuroscience Department at LKSM at Temple University, Philadelphia, Pennsylvania, United States
- Texas Neurology, Dallas, Texas, United States
- Swedish Medical Center, Seattle, Washington, United States
- University of Washington, Seattle, Washington, United States
- UZ Leuven, Leuven, Belgium
- Genge Partners, Montreal, Quebec, Canada
- ALS Clinic Bonn University, Bonn, Germany
- UMC Utrecht, Utrecht, Netherlands
- Linden sp. z o. o. sp. k., Krakow, Poland
- City Clinic Research Sp. z o.o., Warsaw, Poland
- Studieenheten Akademiskt specialistcentrum, Stockholm, Sweden
Other microbiome trials you might be interested in
Muscular Atrophy, Spinal
In this study, researchers will learn more about the effects and safety of BIIB115, also known as salanersen.
Specifica…
Chicago, United StatesEst. completion Nov 28, 2028
Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this stu…
Scottsdale, United StatesEst. completion Mar 2027